A clinical trial of a chemotherapy regimen for advanced classical Hodgkin’s lymphoma demonstrated that an increase in CD68+ macrophages in the TME post-treatment was closely associated with poor prognosis, and CD68 could even be applied as a poor prognostic marker [25]. This evidence concerns the gene CD68 and Hodgkins lymphoma.